GNI Group Ltd. (GNIIF)
15.50
0.00 (0.00%)
USD |
OTCM |
Oct 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 865.36M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -2.82% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 5.013 |
| Price to Book Value | 3.478 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.1254 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 65.98% |
Profile
| GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Pharmaceutical and Medical Device Business. The Pharmaceutical segment includes in IceLui, pharmaceutical development, other pharmaceuticals, reagents. The Medical Device segment designated manufacturer and distributor of biomaterials and medical devices, domestic clinical trial administrator services, fabrication of dental prosthetics, dental technology using CAD/CAM, and dental clinic consulting. The company was founded in November 2001 and is headquartered in Tokyo, Japan. |
| URL | http://www.gnipharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 13, 2026 |
| Last Earnings Release | Aug. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Pharmaceutical and Medical Device Business. The Pharmaceutical segment includes in IceLui, pharmaceutical development, other pharmaceuticals, reagents. The Medical Device segment designated manufacturer and distributor of biomaterials and medical devices, domestic clinical trial administrator services, fabrication of dental prosthetics, dental technology using CAD/CAM, and dental clinic consulting. The company was founded in November 2001 and is headquartered in Tokyo, Japan. |
| URL | http://www.gnipharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 13, 2026 |
| Last Earnings Release | Aug. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |